

GGX Gold Corp.

16:01 06 Dec 2019

NA Proactive news snapshot: Minera Alamos, Orgenesis, Seelos Therapeutics, Capstone Turbine UPDATE ...

Minera Alamos Inc (CVE:MAI) (OTCMKTS:MAIFF) has reached a C\$14 million financing deal with Osisko Gold Royalties Ltd, allowing it to begin construction at its Santana gold mine in Sonora, Mexico. Under the terms of the agreement, Osisko will purchase 30 million shares of Minera at \$0.20 each for a total of \$6 million. In addition, Osisko will acquire a 3% net smelter royalty of the Santana project for \$5 million in cash and Minera will have the option to draw down from Osisko as much as \$3 million more. "We appreciate the ongoing support and backing that our operating team has received from Osisko Gold Royalties," Minera CEO Darren Koningen said in a statement. "This financing package allows the company to begin its transition from gold project developer to gold producer. Today's news sets the stage for an extremely busy and exciting 2020 as our team executes our business plan to the benefit of all our shareholders."

Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, revealed Friday that it struck a strategic partnership agreement between the Theracell-Orgenesis joint venture and the large HYGEIA Group which runs three hospitals in Greece. In a statement, the Germantown, Maryland-based company said that under the terms of the agreement, the joint venture will implement Orgenesis' point-of-care cell therapy platform for clinical development and commercialization of cell and gene therapies within the HYGEIA Group's network of hospitals in Greece. The main goal is to reduce the cost and complexity of supplying cell and gene therapies, said Orgenesis, as well as boost quality by integrating automated processing units and proprietary technologies.

Broker Roth Capital Partners applauded New York clinical-stage biopharmaceutical company Seelos Therapeutics Inc's (NASDAQ:SEEL) recent shift towards using its drug SLS-002 to treat major depressive disorder (MDD) rather than post-traumatic stress disorder (PTSD). Roth analysts view MDD as a "more substantial commercial opportunity" and potential for quicker trial enrollment. The broker reiterated a 'Buy' rating for the stock. Analyst Yasmeen Rahimi noted that Seelos received FDA fast track designation for SLS-002 for the treatment of Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) on November 18. "This development not only highlights FDA's recognition of the high unmet need for MDD patients, but also allows for more frequent communication with the FDA and potential for Accelerated Approval or Priority Review, which could expedite SLS-002's path to approval," said the analyst.

Capstone Turbine Corporation (NASDAQ:CPST), the maker of low-emission, clean-energy microturbines, announced Wednesday that it has appointed Frederick Hencken III as the company's chief financial officer. Hencken, who is currently the interim CFO will step up to being the CFO from January 1, 2020. He will continue to serve as the company's chief accounting officer, principal financial officer and principal accounting officer. Hencken became the interim CFO on October 1 and has served as the company's chief accounting officer since April 2019.

Price: 0.08

Market Cap: \$1.88 m

1 Year Share Price Graph



Share Information

Code: GGX

Listing: TSX-V

52 week	High	Low
	0.33	0.07

Sector: Gold & silver

Website: ggxgold.com

Company Synopsis:

GGX Gold Corp's (TSX. v:GGX) Gold Drop property is situated in one of the most prolific gold-copper mining camps of North America, the Greenwood-Republic mining camp. The current 2019 drill program is following up on the 2018 drilling which intercepted high grade gold-silver results (129 g/t gold and 1,154 g/t silver over 7. 28 meter) from the near surface COD vein which is projected to be 1. 5 kms in length.

action@proactiveinvestors.com

GGX Gold Corp (CVE:GGX) (OTCMKTS:GGXXF) told investors that it had hit 235 metres (m) of magnetite mineralization with a hole into the large, deep geophysical anomaly at its flagship Gold Drop project in British Columbia. As reported in the summer, the anomaly, which was interpreted as a pipe-like structure measuring 1,834 by 1,377 m, was identified by Earth Science Services of Ontario.

Ximen Mining Corp (CVE:XIM) (OTCMKTS:XXMMF) told investors Friday that its optionee GGX Gold Corp (CVE:GGX) (OTCMKTS:GGXXF) had updated on exploration at drilling on the Gold Drop property in the Greenwood camp in BC. Following an intensive campaign on the C.O.D veins, the last hole drilled in 2019 was one, which was sunk into the large, deep geophysical anomaly at its flagship Gold Drop project.

Newrange Gold Corp (CVE:NRG) (OTCMKTS:NRGOF) said the TSX Venture Exchange has accepted the company's filing of the asset purchase agreement dated November 1 between Newrange and its wholly-owned subsidiary Corporacion Minera De Colombia SAS, and Goldmining Inc and its subsidiary Goldmining Exploraciones SAS. Newrange plans to sell a 100% interest in its Yarumalito gold project, paving the way to disposing of all its Colombian assets. Newrange's flagship project is the Pamlico project in Nevada, in the United States.

LeanLife Health Inc (CSE:LLP), a producer of omega-3 products, has agreed to settle \$786,550 of outstanding debt by offering roughly 15.7 million units at \$0.05 per unit. Each unit contains one common share and one common share purchase warrant exercisable at \$0.075 per share over the following 24 months. The company noted that directors and officers will participate in the offering, converting \$310,000 in outstanding fees into 6.2 million units. All shares involved in the offering are subject to a four-month hold.

Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, revealed Friday that it struck a strategic partnership agreement between the Theracell-Orgenesis joint venture and the large HYGEIA Group which runs three hospitals in Greece. In a statement, the Germantown, Maryland-based company said that under the terms of the agreement, the joint venture will implement Orgenesis' point-of-care cell therapy platform for clinical development and commercialization of cell and gene therapies within the HYGEIA Group's network of hospitals in Greece. The main goal is to reduce the cost and complexity of supplying cell and gene therapies, said Orgenesis, as well as boost quality by integrating automated processing units and proprietary technologies.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of GGX Gold Corp. named herein, including the promotion by the Company of GGX Gold Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).